SMAIO Philippe Roussouly

"Dear Madam, Dear Sir, 

In the first half of 2023, we have efficiently deployed our strategic plan in the United States, leveraging our collaboration with NuVasive and training local prescribing surgeons to enable the spread of our i-kontrol offering. At the same time, we have improved our profitability indicators, with margins on implant sales reaching 67% thanks to the optimization of our purchasing conditions. Finally, we have pursued a targeted R&D policy which has enabled us to preserve our cash position in preparation for our commercial expansion. Building on these achievements, we look forward to the coming half-years with confidence, as we continue to implement our strategic plan, which will focus primarily on increasing our sales and boosting our profitability.”

Chairman and CEO